Approval Background

Risutin is an anti‑vascular endothelial growth factor (anti‑VEGF) therapy indicated for neovascular age‑related macular degeneration (AMD). Phase III clinical data demonstrated superior visual‑acuity improvement and safety compared with existing treatments. These findings were pivotal in securing EMA marketing authorization.

Competitive Positioning

In the European market, Risutin showed a higher rate of visual‑acuity recovery relative to the established anti‑VEGF agent Avastin (bevacizumab). It also differentiates itself from the subsequently launched Irelia (aflibercept) through distinct indications and dosing schedules, establishing it as a premium product in ocular therapeutics.

Reimbursement and Market Access Constraints

Health authorities across EU member states prioritize cost‑effectiveness, leading to a phased expansion of reimbursement for Risutin. Initial coverage was limited due to the drug’s high price, but as long‑term vision‑preserving benefits have been validated, the scope of reimbursement is gradually widening. Nonetheless, price burden and treatment accessibility remain barriers to broader market penetration.

Market Size and Outlook

The EMA report outlines the prevalence of neovascular AMD in Europe and projects the associated treatment market size. While exact figures are not disclosed, the analysis anticipates a market worth several billion euros annually, serving millions of patients. This underscores significant revenue growth potential for Risutin and comparable products.